Literature DB >> 31153827

Lipidoid-siRNA Nanoparticle-Mediated IL-1β Gene Silencing for Systemic Arthritis Therapy in a Mouse Model.

Ping Song1, Chuanxu Yang2, Jesper Skovhus Thomsen3, Frederik Dagnæs-Hansen3, Maria Jakobsen4, Annemarie Brüel3, Bent Deleuran5, Jørgen Kjems6.   

Abstract

Interleukin-1 beta (IL-1β) plays a central role in the induction of rheumatoid arthritis (RA). In the present study, we demonstrated that lipidoid-polymer hybrid nanoparticle (FS14-NP) can efficiently deliver siRNA against IL-1β (siIL-1β) to macrophages and effectively suppress the pathogenesis of experimental arthritis induced by collagen antibody (CAIA mice). FS14-NP/siIL-1β achieved approximately 70% and 90% gene-silencing efficiency in the RAW 264.7 cell line and intraperitoneal macrophages, respectively. Intravenous administration of FS14-NP/siRNA led to rapid accumulation of siRNA in macrophages within the arthritic joints. Furthermore, FS14-NP/siIL-1β treatment lowered the expression of pro-inflammatory cytokines in arthritic joints and dramatically attenuated ankle swelling, bone erosion, and cartilage destruction. These results demonstrate that FS14-NP/siIL-1β may represent an effective therapy for systemic arthritis and other inflammatory disorders.
Copyright © 2019 The American Society of Gene and Cell Therapy. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  IL-1β; lipidoid; nanoparticles; rheumatoid arthritis; siRNA delivery

Mesh:

Substances:

Year:  2019        PMID: 31153827      PMCID: PMC6697342          DOI: 10.1016/j.ymthe.2019.05.002

Source DB:  PubMed          Journal:  Mol Ther        ISSN: 1525-0016            Impact factor:   11.454


  61 in total

Review 1.  Preclinical and clinical development of siRNA-based therapeutics.

Authors:  Gulnihal Ozcan; Bulent Ozpolat; Robert L Coleman; Anil K Sood; Gabriel Lopez-Berestein
Journal:  Adv Drug Deliv Rev       Date:  2015-02-07       Impact factor: 15.470

2.  Proposal for a new nomenclature of disease-modifying antirheumatic drugs.

Authors:  Josef S Smolen; Désirée van der Heijde; Klaus P Machold; Daniel Aletaha; Robert Landewé
Journal:  Ann Rheum Dis       Date:  2013-09-26       Impact factor: 19.103

Review 3.  Mechanisms of disease: the molecular and cellular basis of joint destruction in rheumatoid arthritis.

Authors:  Ulf Müller-Ladner; Thomas Pap; Renate E Gay; Michel Neidhart; Steffen Gay
Journal:  Nat Clin Pract Rheumatol       Date:  2005-12

4.  Targeting NF-kB signaling with polymeric hybrid micelles that co-deliver siRNA and dexamethasone for arthritis therapy.

Authors:  Qin Wang; Hao Jiang; Yan Li; Wenfei Chen; Hanmei Li; Ke Peng; Zhirong Zhang; Xun Sun
Journal:  Biomaterials       Date:  2017-01-11       Impact factor: 12.479

5.  Inhibition of notch signalling ameliorates experimental inflammatory arthritis.

Authors:  Jong-Sung Park; Seol-Hee Kim; Kwangmeyung Kim; Cheng-Hao Jin; Ki Young Choi; Jiyeon Jang; Yuri Choi; A-Ryeong Gwon; Sang-Ha Baik; Ui Jeong Yun; Su Young Chae; Seulki Lee; Young Mo Kang; Kang Choon Lee; Thiruma V Arumugam; Mark P Mattson; Jae Hyung Park; Dong-Gyu Jo
Journal:  Ann Rheum Dis       Date:  2013-11-19       Impact factor: 19.103

6.  Controlled and sustained delivery of siRNA/NPs from hydrogels expedites bone fracture healing.

Authors:  Yuchen Wang; Dominic W Malcolm; Danielle S W Benoit
Journal:  Biomaterials       Date:  2017-06-04       Impact factor: 12.479

7.  Isolation and culture of murine macrophages.

Authors:  John Q Davies; Siamon Gordon
Journal:  Methods Mol Biol       Date:  2005

Review 8.  Cytokines in the pathogenesis of rheumatoid arthritis.

Authors:  Iain B McInnes; Georg Schett
Journal:  Nat Rev Immunol       Date:  2007-06       Impact factor: 53.106

9.  Efficacy and safety of the human anti-IL-1β monoclonal antibody canakinumab in rheumatoid arthritis: results of a 12-week, Phase II, dose-finding study.

Authors:  Rieke Alten; Juan Gomez-Reino; Patrick Durez; Andre Beaulieu; Anthony Sebba; Gerhard Krammer; Ralph Preiss; Udayasankar Arulmani; Albert Widmer; Xavier Gitton; Herbert Kellner
Journal:  BMC Musculoskelet Disord       Date:  2011-07-07       Impact factor: 2.362

10.  Development of chronic inflammatory arthropathy resembling rheumatoid arthritis in interleukin 1 receptor antagonist-deficient mice.

Authors:  R Horai; S Saijo; H Tanioka; S Nakae; K Sudo; A Okahara; T Ikuse; M Asano; Y Iwakura
Journal:  J Exp Med       Date:  2000-01-17       Impact factor: 14.307

View more
  5 in total

Review 1.  RNA delivery by extracellular vesicles in mammalian cells and its applications.

Authors:  Killian O'Brien; Koen Breyne; Stefano Ughetto; Louise C Laurent; Xandra O Breakefield
Journal:  Nat Rev Mol Cell Biol       Date:  2020-05-26       Impact factor: 94.444

2.  Preparation, Biosafety, and Cytotoxicity Studies of a Newly Tumor-Microenvironment-Responsive Biodegradable Mesoporous Silica Nanosystem Based on Multimodal and Synergistic Treatment.

Authors:  Zelai He; Huijun Zhang; Hongwei Li; Yanyan Wang; Jing Qian; Xixi Cai; Li Sun; Jingwen Huang
Journal:  Oxid Med Cell Longev       Date:  2020-11-05       Impact factor: 6.543

Review 3.  Nanomedicines for the treatment of rheumatoid arthritis: State of art and potential therapeutic strategies.

Authors:  Qin Wang; Xianyan Qin; Jiyu Fang; Xun Sun
Journal:  Acta Pharm Sin B       Date:  2021-03-12       Impact factor: 11.413

Review 4.  Recent advances in siRNA delivery mediated by lipid-based nanoparticles.

Authors:  Sei Yonezawa; Hiroyuki Koide; Tomohiro Asai
Journal:  Adv Drug Deliv Rev       Date:  2020-08-06       Impact factor: 15.470

Review 5.  Nanomaterials Manipulate Macrophages for Rheumatoid Arthritis Treatment.

Authors:  Shuang Li; Jin Su; Wei Cai; Jian-Xin Liu
Journal:  Front Pharmacol       Date:  2021-07-14       Impact factor: 5.810

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.